Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Salmonella-Type Heptaacylated Lipid A Is Inactive and Acts as an Antagonist of Lipopolysaccharide Action on Human Line Cells

Ken-ichi Tanamoto and Satoko Azumi
J Immunol March 15, 2000, 164 (6) 3149-3156; DOI: https://doi.org/10.4049/jimmunol.164.6.3149
Ken-ichi Tanamoto
Division of Microbiology, National Institute of Health Sciences, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoko Azumi
Division of Microbiology, National Institute of Health Sciences, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The stimulation of both THP-1 and U937 human-derived cells by Salmonella lipid A preparations from various strains, as assessed by TNF-α induction and NF-κB activation, was found to be very low (almost inactive) compared with Escherichia coli lipid A, but all of the lipid As exerted strong activity on mouse cells and on Limulus gelation activity. Experiments using chemically synthesized E. coli-type hexaacylated lipid A (506) and Salmonella-type heptaacylated lipid A (516) yielded clearer results. Both lipid A preparations strongly induced TNF-α release and activated NF-κB in mouse peritoneal macrophages and mouse macrophage-like cell line J774-1 and induced Limulus gelation activity, although the activity of the latter was slightly weaker than that of the former. However, 516 was completely inactive on both THP-1 and U937 cells in terms of both induction of TNF-α and NF-κB activation, whereas 506 displayed strong activity on both cells, the same as natural E. coli LPS. In contrast to the action of the lipid A preparations, all the Salmonella LPSs also exhibited full activity on human cells. However, the polysaccharide portion of the LPS neither exhibited TNF-α induction activity on the cells when administered alone or together with lipid A nor inhibited the activity of the LPS. These results suggest that the mechanism of activation by LPS or the recognition of lipid A structure by human and mouse cells may differ. In addition, both 516 and lipid A from Salmonella were found to antagonize the 506 and E. coli LPS action that induced TNF-α release and NF-κB activation in THP-1 cells.

The biological activity of lipid A depends on its chemical structure, and extraordinary progress has been made on the relationship between chemical structure and biological activity of lipid A by using chemically synthesized lipid A analogues (1). Recently, several nontoxic lipid As that closely chemically resemble active lipid A but are completely devoid of endotoxic activity have been reported (2, 3, 4). Many of these preparations have also been found to act as antagonists (3, 5, 6), and simple chemical modifications have also been found to change biologically active lipid A to completely nontoxic derivatives (7, 8). These findings indicate that the biological activity of lipid A is controlled by fine structural variations that are still ill-defined. In addition, cells of different species have been discovered to respond in different ways to certain lipid A derivatives, such as lipid A precursor structure, which is an agonist in mouse cells but an antagonist in human cells (9, 10, 11), indicating that the cells (or receptor molecules) discriminate fine differences in the chemical structure of lipid A. These findings indicate that understanding the biological activity of lipid A is not a simple task and that the mechanism of action of lipid A is different in humans and mice.

Escherichia coli- and Salmonella-type lipid A have the most typical lipid A structures so far defined, and both have been synthesized chemically (12, 13, 14) and well characterized biologically by many investigators (15, 16, 17, 18, 19, 20). The chemical structure of these lipid As consists of a hexa- and heptaacylated diglucosamine bearing six and seven fatty acids, respectively, as shown in Fig. 1⇓. The only structural difference between them is the hexadecanoyl acid attached to the hydroxyl residue of 3-hydroxy tetradecanoic acid bound to the 2 position of reducing glucosamine.

           FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Structure of E. coli-type hexaacylated and Salmonella-type heptaacylated lipid A molecules synthesized chemically (506 and 516, respectively).

Previous studies on structure-activity relationships performed by using chemically synthesized analogues have revealed that Salmonella-type lipid A is one of the active lipid As and exhibited activity in all of the test systems employed at that time, although its activity was a little less than that of E. coli-type synthetic lipid A, which has, therefore, been subsequently recognized as representative of the structure of active lipid A.

In view of the species-specific actions of endotoxin, it is necessary to clarify the actual action of lipid A molecules on human cells to better understand endotoxicosis, and thus the activity of endotoxin must be considered based on its actions on human cells.

In this study, we show that one of the typical lipid As from Salmonella is not an activator on human cells.

Materials and Methods

Materials

Recombinant TNF-α standards and rabbit polyclonal antisera against murine TNF-α were obtained from Asahi Kasei Kogyo (Tokyo, Japan). Rabbit IgG was obtained from Zymed Laboratories (South San Francisco, CA). Anti-human and -mouse IκB-α antisera (1309 and 751, respectively) were gifts from Dr. Nancy Rice (Advanced BioScience Laboratories-Basic Research Program, National Cancer Institute-Frederick Cancer Research and Development Center). Synthetic lipid A analogues 506 and 516 were a gift of Daiichi Kagaku (Tokyo, Japan). RPMI 1640 medium with glutamine and IMDM were the products of Life Technologies (Grand Island, NY). Quantitative Limulus assay reagent (Endospecy) was obtained from Seikagaku Kogyo (Tokyo, Japan). Pyrogen-free water was a product of Otsuka Seiyaku (Tokyo, Japan). LPS was extracted from E. coli 03K2a2b:H2, Salmonella minnesota (S type), Salmonella typhimurium LT2, and Salmonella abortus equi by the aqueous phenol method (21). Lipid A was obtained as an insoluble substance after 1% acetic acid treatment of LPS at 100°C for 90 min (22). The polysaccharide portion was obtained from the supernatant of the reaction mixture by evaporating to dryness and washing with chloroform three times. No residual lipid A portion was detected by either fatty acid analysis by Gas chromatography or by Limulus gelation assay.

Gas-liquid chromatography conditions

Gas-liquid chromatography analysis was performed on a model GC-14A (Shimadzu, Kyoto, Japan) with a HiCap-CBM5 fused silica capillary column (25 m × 0.25 mm; GL Science, Toyko, Japan) and temperature programs 120°C for 3 min to 250°C at 3°C/min. Nitrogen was used as carrier gas.

Mass spectrometry

Liquid secondary-ion mass spectrometry was performed on a VG ZAB-2SEQ spectrometer (VG Analytical, Manchester, U.K.) operated at 8 kV in a negative mode. The cesium gun was operated at 30 kV. Current-controlled scans were acquired at a rate of 30 s per decade. A mixture of ethanolamine and m-nitrobenzyl alcohol (1:1) was used as the matrix.

Induction of TNF-α release from mouse peritoneal macrophages, J774-1, THP-1, and U937 cells

Mouse peritoneal macrophages were obtained by washing the peritoneal cavity of female BALB/c mice (6–10 wk old, Japan SLC, Hamamatsu, Japan) with 5 ml of serum-free IMDM (23). The cell number was adjusted to 2 × 106 cells/ml. After adhesion, the cells were incubated with the stimulant for 6 h. J774-1, THP-1, and U937 cells were grown in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated FCS, 50 μM 2-ME, 5 mM HEPES, penicillin (100 U/ml), and streptomycin (100 μg/ml) in a 5% CO2 atmosphere at 37°C. J774-1 cells were harvested by scraping with cell scraper (Costar, Cambridge, MA) and suspended in a fresh medium. The cells (1 × 106 cells/ml/well of 24-well dishes) were allowed to adhere to plastic for 3 h at 37°C, washed twice with medium, and incubated an additional 4 h for TNF-α induction with the stimulant. THP-1 cells (2 × 105 cells/ml/well of 24-well dishes) were prepared for the experiments by adding 100 ng/ml of PMA (Sigma, St. Louis, MO) and 0.1 μM 1,25-dihydroxy vitamin D3 (Wako Pure Chemical Industries, Tokyo, Japan) to cell suspensions in RPMI 1640 medium with 10% FCS (11, 24). The cell suspensions were allowed to differentiate and adhere to plastic for 72 h at 37°C. After washing, the cells were incubated an additional 24 h with the stimulant. U937 cells (1 × 106 cells/ml/well of 24-well dishes) were prepared for the experiments by adding 100 ng/ml of PMA to cell suspensions in RPMI 1640 medium with 10% FCS (25). The cell suspensions were allowed to differentiate and adhere to plastic for 48 h at 37°C. After washing, the cells were incubated an additional 8 h with the stimulant. The supernatant of the test samples was stored at −80°C until used to determine TNF-α.

TNF-α assay

The TNF-α produced was measured by cytotoxicity assay against L929 murine fibroblast cells. L929 cells were grown in tissue culture flasks in RPMI 1640 medium (Life Technologies) supplemented with 10% FCS, 50 μM 2-ME, 5 mM HEPES, penicillin (100 U/ml), and streptomycin (100 μg/ml). Cells were detached with trypsin, washed, resuspended in medium at 4 × 105 cells/ml, and 100 μl aliquots were plated in 96-well flat-bottom plates (catalog no. 25860-96; Corning Glass, Corning, NY). After incubation for 3–5 h at 37°C in 5% CO2, 50 μl of actinomycin D (4 μg/ml) in RPMI 1640 medium was added to each well, and 50 μl of test sample was then added to the wells (final volume; 200 μl/well). The results are expressed as means of triplicate determinations. To determine whether the cytotoxic activity against L929 cells was due to TNF-α, aliquots of supernatants from macrophage culture were incubated for 12 h with polyclonal rabbit antiserum to TNF-α using nonspecific IgG as the control. The polyclonal Ab to TNF-α completely abolished the cytotoxicity of the supernatants in all the samples tested.

Activation of NF-κB

Endotoxin-mediated NF-κB activation was assessed by analyzing the degradation of IκB-α protein in the cytosol fraction by Western blotting (26, 27, 28).

Crude cytosol fractions of LPS-treated and -untreated cells were prepared as follows (29). J774-1 cells (2 × 106/2.5 ml/well of 6-well dishes) or THP-1 cells (1.25 × 106/well) pretreated with 20 μg/ml of cycloheximide for 30 min were treated with the test sample for 15 and 60 min, respectively, and washed once at 4°C with 5 ml of PBS and were immediately frozen. The frozen cells were lysed on ice for 10 min with 100 μl of lysis buffer (10 mM HEPES-KOH, 5 mM EDTA, and 10 mM KCl, pH 7.9) containing 0.5% (for J774-1) or 0.1% (for THP-1) Nonidet P-40, 1 mM DTT, and a protease inhibitor mixture (Boehringer Mannheim, Mannheim, Germany). The lysate was centrifuged for 5 min at 15,000 rpm at 4°C, and the resultant supernatant was used as the crude cytosol fraction.

The crude cytosol fractions (50 μg of protein) were subjected to 10% SDS-PAGE, and IκB-α was detected as follows. Protein was transferred for 1 h onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) with a semidry blotting apparatus. The membrane was then probed with human (or mouse) IκB-α antisera (1:1000 dilution) followed by a peroxide-labeled goat anti-rabbit IgG Ab (Boehringer Mannheim; diluted 1:10000). Proteins were detected by using an enhanced chemiluminescence system (Amersham, Arlington Heights, IL).

Limulus amoebocyte gelation activity

Activation of the proclotting enzyme of the horseshoe crab was tested by a quantitative Limulus assay reagent (Endospecy). Pyrogen-free water was used to dilute the test samples. A 50-μl amount of each sample was incubated with the same volume of lysate containing chromogenic substrate in 96-well flat plates (Costar) for 30 min at 37°C. The reaction was stopped by adding 200 μl of 0.6 M acetic acid. The chromogen (p-nitroaniline) was measured at 405 nm using a microplate reader (Molecular Devices, Menlo Park, CA).

Inhibition assay of endotoxin-mediated TNF-α induction and NF-κB activation in THP-1 cells

Inhibition of endotoxin-mediated TNF-α induction and NF-κB activation in THP-1 cells were performed by adding the indicated concentration of the inhibitor to the assay system followed immediately by the addition of agonist, and TNF-α production or the degradation of IκB-α was compared with a control containing agonist alone. Inhibition of TNF-α induction is expressed as percent TNF-α production with production in the presence of agonist alone equal to 100%.

Results

Fatty acid composition and liquid secondary-ion mass spectrometry analysis of lipid As from Salmonella and E. coli LPS

To examine the fatty acid composition of LPS and lipid A from the Salmonella species used in the present study, i.e., S. abortus equi, S. minnesota (S type), and S. typhimurium LT2 lipid As were hydrolyzed, and the methyl-fatty acids liberated were analyzed by gas-liquid chromatography. The results are shown in Table I⇓, where the molar ratios of the fatty acids are expressed by assuming the number of 3-hydroxytetradecanoic acid molecules in each LPS to be 4. The composition of all the lipid As was very similar, with the major component of all these lipid A preparations being heptaacylated diglucosamine lipid A, as also confirmed by the results of mass-spectrometry (data not shown).

View this table:
  • View inline
  • View popup
Table I.

Fatty acid composition of lipid A from various Salmonella and E. coli LPSa

Salmonella LPS and lipid A induction of TNF-α release by mouse peritoneal macrophages and mouse macrophage-like J774-1 cells

TNF-α release into the medium was estimated by cytotoxicity against actinomycin-D-sensitized L929 murine fibroblasts. Murine peritoneal macrophages were found to react to stimulation by all Salmonella LPSs from the three different species, S. abortus equi, S. minnesota, and S. typhimurium. As shown in Fig. 2⇓A, the cells started to secrete TNF-α at a LPS concentration of 0.1 ng/ml, and TNF-α production by the macrophages increased dose-dependently. Although the activity of the lipid A preparations was less than that of their respective parent LPS, they stimulated cells at a concentration of 1–10 ng/ml.

           FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Salmonella LPS and lipid A induction of TNF-α release by mouse cells. A, Murine peritoneal macrophages. B, J774-1 cells. Cells (A, 2 × 106 cells/ml/well of 24-well dishes in IMDM; B, 1 × 106 cells/ml/well in RPMI 1640 medium supplemented with 10% (v/v) FCS) were cultured with test sample. After 6 h (A) or 4 h (B) of incubation at 37°C, the supernatants were examined for TNF-α. The results are expressed as means ± SD for triplicate wells from one of three experiments with similar results.

A similar response to Salmonella LPS and lipid A was observed in mouse macrophage-like J774-1 cells. Although the activity of each of the lipid As was about 10 times less than that of its parent LPS, the same as in mouse peritoneal macrophages with regard to the minimum stimulatory dose, significant TNF-α production was recognized at a dose of 1 ng/ml (Fig. 2⇑B).

Salmonella LPS and lipid A induction of TNF-α release by THP-1 and U937 line cells

Human THP-1 and U937 line cells also reacted to stimulation with all three Salmonella LPSs, and both lines started to secrete TNF-α at a concentration of 10 ng/ml. The LPS-induced production of TNF-α increased dose-dependently (Fig. 3⇓). However, the cells did not produce TNF-α when exposed to any of the lipid A preparations, and significant amounts of TNF-α were first detected at a concentration of 10 μg/ml in THP-1 cells, showing that the activity of each lipid A was 103 times less or more than that of their parent LPS.

           FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Salmonella LPS and lipid A induction of TNF-α release by human line cells. A, Human THP-1 cells. Cells (2 × 105 cells/ml/well) were incubated with 100 ng/ml of PMA and 0.1 μM 1,25-dihydroxyvitamin D3 for 3 days in RPMI 1640 medium containing 10% FCS at 37°C. B, Human U937 cells. Cells (1 × 106 cells/ml/well) were incubated with 100 ng/ml of PMA for 2 days in RPMI 1640 medium containing 10% FCS at 37°C. After an additional 24 h (A, THP-1) or 8 h (B, U937) of incubation in medium containing 10% FCS with 10 μl of test sample, the supernatants were assayed for TNF-α. Values represent the mean concentration of TNF-α SD for triplicate wells from one of three experiments with similar results.

E. coli- and Salmonella-type synthetic lipid A induction of TNF-α release by mouse peritoneal macrophages and mouse macrophage-like J774-1 cells

Lipid A preparations obtained from natural LPS are usually heterogeneous, and all of the lipid A preparations from Salmonella LPS used in the present study partially included a significant amount of E. coli-type lipid A and may also have included contaminating parent LPS, both of which stimulate human cells. Because the data obtained by using these preparations are, therefore, not reliable, the same experiments described above were performed with chemically synthesized Salmonella-type lipid A (516; Fig. 1⇑) using E. coli-type synthetic lipid A (506; Fig. 1⇑) as a control. The results in mouse cells are shown in Fig. 4⇓, A and B. Murine peritoneal macrophages reacted to stimulation with 516 in a dose-dependent manner and started to secrete TNF-α at a concentration of 10 ng/ml (Fig. 4⇓A). A similar response to 516 was also observed in mouse macrophage-like J774-1 cells (Fig. 4⇓B). The activity of 506 in inducing TNF-α was greater than that of 516, and the activity was expressed even at 1 ng/ml in both mouse peritoneal and J774-1 line cells, showing that its activity is about ten times more powerful than that of 516.

           FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

E. coli- and Salmonella-type synthetic lipid A induction of TNF-α release by mouse and human cells. A, Murine peritoneal macrophages. B, J774-1 cells. C, Human THP-1 cells. D, Human U937 cells. Experiments were performed as described in Figs. 2⇑ and 3⇑. The results are expressed as means ± SD of triplicate wells from one of two experiments with similar results.

Synthetic lipid A, 506 and 516, induction of TNF-α release by THP-1 and U937 line cells

Human THP-1 and U937 line cells also reacted to stimulation with E. coli-type hexaacylated lipid A and started to secrete significant amounts of TNF-α at a concentration of 1 ng/ml. The LPS-induced production of TNF-α by both cells increased dose-dependently (Fig. 4⇑, C and D). In contrast, neither human THP-1 or U937 cells of produced TNF-α at all when stimulated with 516, even at a concentration of 10 μg/ml (Fig. 4⇑, C and D).

Activation of NF-κB in mouse macrophage-like J774-1 cells by Salmonella LPS and lipid A, and E. coli- and Salmonella-type synthetic lipid As

To examine endotoxin-mediated NF-κB activation, J774-1 cells were treated with LPS and lipid A from S. abortus equi, and cell extracts were analyzed for degradation of IκB-α protein by immunoblotting. The results are shown in Fig. 5⇓A. Stimulation of the cells with both S. abortus equi LPS and lipid A resulted in a rapid decrease and disappearance of IκB-α protein at 1 ng/ml ml and 10 ng/ml, respectively. Both synthetic lipid A preparations 506 and 516 also expressed strong IκB-α degrading activity in J774-1 cells (Fig. 5⇓B). However, the activity of 506 was about ten times stronger than that of 516, consistent with the results of TNF-α induction.

           FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Activation of NF-κB in mouse cells by Salmonella LPS and lipid A, and synthetic lipid As. Endotoxin-mediated NF-κB activation was examined by analyzing for degradation of IκB-α. J774-1 cells (2 × 106/2.5 ml/well) were treated with indicated concentrations of test sample for 15 min. Cytosol extracts were prepared and the IκB-α levels were analyzed by Western blotting (50 μg protein/lane).

Activation of NF-κB in THP-1 line cells by Salmonella LPS and lipid A, and synthetic lipid As

Human THP-1 line cells also reacted to stimulation with Salmonella LPS and E. coli-type hexaacylated lipid A, and IκB-α protein degradation started at a concentration of 1 ng/ml (Fig. 6⇓, A and B). In contrast, Salmonella lipid A exhibited much less activity than the parent LPS (104 times less), and Salmonella type synthetic lipid A did not induce degradation of IκB-α at all, even at a concentration of 1 μg/ml (Fig. 6⇓).

           FIGURE 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6.

Activation of NF-κB in human cells by Salmonella LPS and lipid A, and synthetic lipid As. THP-1 cells (1.25 × 106/well) were treated with cycloheximide (20 μg/ml) for 30 min and then with indicated concentrations of test sample for 60 min. Cytosol extracts were prepared and the IκB-α levels were analyzed by Western blotting (50 μg protein/lane).

Limulus amoebocyte gelation activity of Salmonella LPS and lipid A, and synthetic lipid As

Activation of the clotting system cascade of the horseshoe crab was used to assess differences in the activity of Salmonella LPS and lipid A, 506 and 516. The results are shown in Fig. 7⇓. Although the activity of 516 was slightly lower than that of 506, all of the preparations exhibited strong Limulus gelation activity.

           FIGURE 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 7.

Limulus amoebocyte gelation activity of Salmonellaabortus equi LPS and lipid A, and synthetic lipid As. Quantitative Limulus assay reagent was incubated with test samples for 30 min, and the chromogen released was measured. ▴, Salmonellaabortus equi LPS; ▵, lipid A; •, 506; and ▪, 516.

Inhibition of the TNF-α induction activity of E. coli LPS and 506 by Salmonella lipid A and 516

Because the lipid A from Salmonella and synthetic Salmonella-type lipid A failed to stimulate TNF-α production by human THP-1 cells, their antagonistic activity on the response of cells to active LPS was tested by adding them to the cell cultures together with the agonist. As shown in Fig. 8⇓, both Salmonella lipid A and synthetic Salmonella-type lipid A displayed inhibitory activity on TNF-α production stimulated by E. coli LPS. Suppression by synthetic Salmonella-type lipid A was observed in a dose-dependent manner without regard to the stimulatory dose of the agonist (10 and 100 ng/ml). Significant inhibitory effects were observed at an agonist to antagonist ratio of 1:10 (w/w), and almost complete inhibition was possible at a 100-fold excess of both antagonists to stimulant.

           FIGURE 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 8.

Inhibitory activity of Salmonella lipid A and 516 on the TNF-α induction activity of E. coli LPS in human cells. Various concentrations of antagonist (A, Salmonella lipid A; B, 516) in 10 μl of water were added to THP-1 cells prepared as described in Fig. 3⇑, followed immediately by the addition of 10 μl of E. coli LPS. After 24 h of incubation at 37°C, the supernatants were assayed for TNF-α. Inhibition is expressed as percent TNF-α production, with TNF-α production in the presence of agonist alone equal to 100%. Values represent the mean % inhibition ± SD for triplicate wells. Concentrations of E. coli LPS: ○, 10 ng/ml; •, 100 ng/ml.

Inhibition by 516 of NF-κB activation induced by E. coli LPS in THP-1 cells

The antagonistic activity of synthetic Salmonella-type lipid A on the response of human THP-1 line cells to IκB-α-degrading activity of 506 was tested. As shown in Fig. 9⇓, synthetic Salmonella-type lipid A (516) displayed inhibitory activity on the degradation of IκB-α in response to 506. An almost total inhibitory effect was observed at an agonist to antagonist ratio of 1:100 (w/w).

           FIGURE 9.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 9.

Inhibitory activity of 516 on the NF-κB activation of E. coli LPS in human cells. Various concentrations of 516 in 10 μl of water were added to THP-1 cells prepared as described in Fig. 6⇑, followed immediately by the addition of 10 μl of 506. After 60 min of incubation at 37°C, cytosol extracts were prepared and the IκB-α levels were analyzed by Western blotting (50 μg protein/lane).

Activity of the polysaccharide portion of Salmonella LPS on induction of TNF-α and inhibition of TNF-α induction by parent LPS in THP-1 line cells

Because the activity of LPS and lipid A from Salmonella on human cells was completely different, the action of the polysaccharide portion from S. abortus equi was examined in regard to TNF-α induction activity and the inhibitory activity on TNF-α induction of active 506. No TNF-α induction by polysaccharide alone was recognized, even at 10 μg/ml, and no LPS activity was recovered when the polysaccharide portion and lipid A from S. abortus equi were added to the cells together (data not shown). Furthermore, the polysaccharide showed no inhibitory activity on the TNF-α induction activity of its parent LPS, even when a 103 times excess of polysaccharide to lipid A (w/w) was added to the cells (10 ng/ml of LPS plus 10 μg/ml of polysaccharide) (data not shown).

Discussion

In the present study, we found that all lipid A preparations isolated from several Salmonella strains exhibited far lower activity on human cells in inducing TNF-α and NF-κB activation than E. coli lipid A. According to the fatty acid analysis by gas-liquid chromatography and mass spectrometry (data not shown), the major lipid A structure of all of the lipid A preparations from the Salmonella strains used in the present study was heptaacylated diglucosamine, which is referred to as Salmonella-type lipid A, because it is the typical structure present in Salmonella, as reported previously (30, 31, 32). In addition to the Salmonella-type lipid A, they also contained a significant amount of E. coli-type hexaacylated diglucosamine lipid A structure.

Because natural lipid A usually consists of a mixture of various structures originated from the biosynthesis and extraction procedure, as was also the case in the present study, and its biological activity depends on the chemical structure, experiments using natural lipid A may give rise to misunderstandings regarding structure-activity relationships.

To confirm the phenomenon observed when natural Salmonella lipid A was used, and to obtain more definitive results, experiments have been performed with synthetic E. coli- and Salmonella-type lipid A (506 and 516, respectively). The results showed that Salmonella-type lipid A is completely inactive on human cells, but is a strong agonist in mice and active in inducting Limulus gelation activity as well. In contrast, E. coli-type lipid A exhibited full activity in human cells as well.

Both of these lipid As, the Salmonella-type heptaacylated and E. coli-type hexaacylated forms, had been successfully synthesized chemically in the past (12, 13, 14), and their biological properties had been carefully tested by many investigators (15, 16, 17, 18, 19, 20). The Salmonella-type lipid A had been demonstrated to be very active in mice and rabbits and subsequently had been thought to be a typical lipid A (18, 19, 20) along with that from E. coli. However, Salmonella-type lipid A (516) was not tested for activity on human systems, and nobody at that time expected that it would be discriminated by human and mouse cells.

Although natural Salmonella lipid A contains a significant amount of the E. coli-type hexaacylated diglucosamine structure, as recognized by mass spectrometry, its activity on human cells was mach lower than expected. In the present study, biologically inactive Salmonella lipid A was found to antagonize the agonist (E. coli LPS and 506) action of inducing TNF-α and NF-κB activation in THP-1 cells. This may explain the low activity of natural lipid A from Salmonella. The apparent activity of Salmonella lipid A must be the result of the overall reaction of active structures, including E. coli-type lipid A, and the antagonistic activity of the Salmonella-type structure.

In contrast to the inactivity of Salmonella lipid A on human cells, all of the parent LPS preparations stimulated human cells to the same extent as E. coli LPS and induced both TNF-α release and NF-κB activation.

The results obtained in the present study are very interesting in two senses. First, the lipid A from Salmonella LPS is specifically inactive on human cells, showing that recognition of the lipid A structure by human cells is different from that of mice or rabbits. The same species-specific phenomenon had been observed with tetraacylated lipid A precursor (lipid IVA), which is also active in mice and rabbits, but inactive on human cells (9, 33). However, the meaning of these two lipid As is completely different in view of the fact that the precursor structure is an intermediate in the biosynthesis of LPS, whose structure is not found as a component of any LPS. In contract, the Salmonella-type heptaacylated lipid A actually exists as the major component of Salmonella lipid A, along with the hexaacylated lipid A, e.g., E. coli-type lipid A.

The second point is that Salmonella lipid A is inactive, but that the LPS exhibits full activity in terms of both the induction of TNF-α release and NF-κB activation in human macrophage-like cells, while both preparations are equally active in the other assay systems employed in the present study, including Limulus gelation activity and the activation of mouse cells, both peritoneal macrophages and the J774-1 line, as shown by many previous studies performed both by us and other investigators. These facts suggest that the polysaccharide portion plays an important role in the manifestation of activity in human cells. However, the polysaccharide portion alone did not activate the cells at all, and no LPS activity was recovered when lipid A and polysaccharide of the same LPS origin were added to the cells simultaneously. Furthermore, the activity of LPS in human cells was not inhibited even by adding a 100 times excess amount of the polysaccharide portion.

The reason why Salmonella lipid A, but not LPS, fails to stimulate human cells, but not mouse cells, is unclear. Until now, the active center of the endotoxic activity of LPS has been thought to reside in the lipid A portion. There have been no reports claiming that the polysaccharide portion plays a role in the activation of macrophages as well as the activation of other endotoxic activities. Although the role of polysaccharide in human cell activation is still unknown, these results suggest that the activation mechanism of LPSs may differ. Recently, Shimazu et al. have reported that MD-2, a molecule that confers LPS responsiveness on Toll-like receptor 4 (TLR4), has broader specificity in the form of the TLR4-MD2 complex than recently described for TLR2 (34), and they suggested that the polysaccharide portion selectively affects recognition by TLR2 (35). All considered, further study concerning the role of the polysaccharide portion in LPS signaling in human cells is needed and is currently under way.

The findings in the present study also suggest that the activity of Salmonella LPS introduced into the body may be altered by circumstances or by host defense mechanisms: Salmonella LPS is easily detoxified because the ketocidic linkage that links lipid A, and the polysaccharide portion is quite susceptible to acidic conditions (36), whereas inactive Salmonella lipid A may change to the active form by being split off the acyloxyacylated fatty acids by the enzyme in macrophages (37, 38). These changes may make understanding the reaction of endotoxin in sepsis complex.

Based on the results of the present and previous studies, it seems that higher animals have higher specificity for the recognition of lipid A structures as observed in the case of lipid A precursor and chemically modified lipid A analogues (39). This seems to suggest that the active endotoxin is effectively detoxified in higher animals.

Experiments concerning the structure-activity relationships of lipid As have mainly been performed in animal systems thus far, and thus an important finding in the present study had been overlooked. Accordingly, the study should be performed again from the viewpoint of human endotoxicosis by using a human system and chemically pure materials.

Acknowledgments

We thank Dr. Nancy Rice for the use of anti-human and -mouse IκB-α antisera (1309 and 751, respectively).

Footnotes

  • ↵1 S.A. was supported by a grant from the Japan Science and Technology Corporation.

  • ↵2 Address correspondence and reprint requests to Dr. Ken-ichi Tanamoto, Division of Microbiology, National Institute of Health, Sciences, 1-18-1 Kamiyoga, Setagayaku, Tokyo 158-8501, Japan. E-mail address: tanamoto{at}nihs.go.jp

  • Received August 9, 1999.
  • Accepted January 3, 2000.
  • Copyright © 2000 by The American Association of Immunologists

References

  1. ↵
    Müller-Loennies, S., U. Zähringer, U. Seydel, S. Kusumoto, A. J. Ulmer, E. Th. Rietschel. 1998. What we know and don’t know about the chemical and physical structure of lipopolysaccharide in relation to biological activity. J. Levin, and M. Pollack, and T. Yokochi, and M. Nakano, eds. Endotoxin and Sepsis 37 Wiley-Liss, New York.
  2. ↵
    Omar, A. S., H. T. Flammann, D. Borowiak, J. Weckesser. 1983. Lipopolysaccharide of two strains of the phototrophic bacterium Rhodopseudomonas capsulata. Arch. Microbiol. 134: 212
    OpenUrlCrossRefPubMed
  3. ↵
    Qureshi, N., K. Takayama, R. Kurtz. 1991. Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect. Immun. 59: 441
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Strittmatter, W., W. Weckesser, P. V. Salimath, C. Galanos. 1983. Nontoxic lipopolysaccharide from Rhodopseudomonas sphaeroides ATCC 17023. J. Bacteriol. 155: 153
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Tanamoto, K., C. Galanos, O. Lüeritz, S. Kusumoto, T. Shiba. 1984. Mitogenic activities of synthetic lipid A analogues and suppression of mitogenicity of lipid A. Infect. Immun. 44: 427
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Christ, W. J., O. Asano, A. L. C. Robidoux, M. Perez, Y. Wang, G. R. Dubuc, W. E. Gavin, L. D. Hawkins, P. D. McGuinness, M. A. Mularkey, et al 1995. E5531, a pure endotoxin antagonist of high potency. Science 268: 80
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Tanamoto, K.. 1994. Predominant role of the substituents on the hydroxyl groups of 3-hydroxy fatty acids of non-reducing glucosamine in lipid A for the endotoxic and antagonistic activity. FEBS Lett. 351: 325
    OpenUrlCrossRefPubMed
  8. ↵
    Tanamoto, K.. 1995. Chemically detoxified lipid A precursor derivatives antagonize the TNF-α-inducing action of LPS in both murine macrophages and a human macrophage cell line. J. Immunol. 155: 5391
    OpenUrlAbstract
  9. ↵
    Loppnow, H., H. Brade, I. Durrbaum, C. A. Dinarello. 1989. IL-1 induction-capacity of defined lipopolysaccharide partial structures. J. Immunol. 142: 3229
    OpenUrlAbstract
  10. ↵
    Kovach, N., E. Yee, R. S. Munford, C. R. H. Raetz, J. M. Harlan. 1990. Lipid IVa inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human blood ex vivo. J. Exp. Med. 172: 77
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Golenbock, D. T., R. Y. Hampton, N. Qureshi, K. Takayama, C. R. H. Raetz. 1991. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem. 266: 19490
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Imoto, M., H. Yoshimura, M. Yamamoto, T. Shimamoto, S. Kusumoto, T. Shiba. 1984. Chemical synthesis of phosphorylated tetraacyl disaccharide corresponding to a biosynthetic precursor of lipid A. Tetrahedron Lett. 25: 2667
    OpenUrlCrossRef
  13. ↵
    Imoto, M., H. Yoshimura, N. Sakaguchi, S. Kusumoto, T. Shiba. 1984. Total synthesis of Escherichia coli lipid A. Tetrahedron Lett. 26: 1545
    OpenUrlCrossRef
  14. ↵
    Kusumoto, S., H. Yoshimura, M. Imoto, T. Shimamoto, T. Shiba. 1985. Chemical synthesis of 1-dephospho derivative Escherichia coli lipid A. Tetrahedron Lett. 26: 909
    OpenUrlCrossRef
  15. ↵
    Galanos, C., O. Lüeritz, M. A. Freudenberg, E. Th. Rietschel, O. Westphal, H. Brade, L. Brade, U. Shade, M. Imoto, H. Yoshimura, et al 1985. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 148: 1
    OpenUrlCrossRefPubMed
  16. ↵
    Homma, J. Y., M. Matsuura, S. Kanegasaki, Y. Kawakubo, Y. Kojima, N. Shibukawa, Y. Kumazawa, A. Yamamoto, K. Tanamoto, T. Yasuda, et al 1985. Structural requirements of lipid A responsible for the functions: a study with chemically synthesized lipid A and its analogues. J. Biochem. 98: 395
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Kotani, S., H. Takada, M. Tsujimoto, T. Ogawa, I. Takahashi, T. Ikeda, K. Otsuka, H. Shimauchi, N. Kasai, J. Mashimo, et al 1985. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from Escherichia coli Re-mutant. Infect. Immun. 49: 225
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Galanos, C., O. Lüderiz, M. Freudenberg, L. Brade, U. Schade, E. Th. Rietschel, S. Kusumoto, T. Shiba. 1986. Biological activity of synthetic heptaacyl lipid A representing a component of Salmonella minnesota R595 lipid A. Eur. J. Biochem. 160: 55
    OpenUrlPubMed
  19. ↵
    Kanegasaki, S., K. Tanamoto, T. Yasuda, J. Y. Homma, M. Matsuura, M. Nakatsuka, Y. Kumazawa, A. Yamamoto, T. Shiba, S. Kusumoto, et al 1986. Structure-activity relationship of lipid A: comparison of biological activities of natural and synthetic lipid As with different fatty acid compositions. J. Biochem. 99: 1203
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Kotani, S., H. Takada, I. Takahashi, M. Tsujimoto, T. Ogawa, T. Ikeda, K. Harada, H. Okamura, T. Tamura, S. Tanaka. 1986. Low endotoxic activities of synthetic Salmonella-type lipid A with an additional acyloxyacyl group on the 2-amino group of β(1–6)glucosamine disaccharide 1–4′-bisphosphate. Infect. Immun. 52: 872
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Galanos, C., O. Lüderitz, O. Westphal. 1969. A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem. 9: 245
    OpenUrlCrossRefPubMed
  22. ↵
    Galanos, C., O. Lüderitz, O. Westphal. 1971. Preparations and properties of antisera against the lipid A component of bacterial lipopolysaccharides. Eur. J. Biochem. 24: 116
    OpenUrlPubMed
  23. ↵
    Tanamoto, K.. 1994. Induction of prostaglandin release from macrophages by bacterial endotoxin. V. L. Clark, and P. M. Bavoil, eds. In Methods in Enzymology Vol. 236: 31 Academic Press, San Diego, CA.
    OpenUrlCrossRefPubMed
  24. ↵
    Kitchens, R. L., T. R. J. Ulevitch, R. S. Munford. 1992. Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophages cell line without inhibiting LPS uptake by a CD14-mediated pathway. J. Exp. Med. 176: 485
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Roberts, F. A., G. J. Richardson, S. M. Michalek. 1997. Effects of Prophyromonas gingivalis and Escherichia coli lipopolysacharides on mononuclear phagocytes. Infect. Immun. 65: 3248
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Cordle, S. R., R. Donald, M. A. Read, J. Hawiger. 1993. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-κB proteins in human monocytic THP-1 cells. J. Biol. Chem. 268: 11803
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Henkel, T., T. Machleidt, I. Alkalay, M. Kronke, Y. Ben Neriah, P. A. Baeuerle. 1993. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365: 182
    OpenUrlCrossRefPubMed
  28. ↵
    Mellits, K. H., R. T. Hay, S. Goodbourn. 1993. Proteolytic degradation of MAD3 (IκB- α) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB. Nucleic Acids Res. 21: 5059
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Muroi, M., Y. Muroi, N. Ito, N. R. Rice, T. Suzuki. 1995. Effects of protease inhibitors on LPS-mediated activation of a mouse macrophage cell line (J774). J. Endotoxin Res. 2: 337
    OpenUrl
  30. ↵
    Rietschel, E. T., H. W. Wollenweber, R. Russa, H. Brade, U. Zahringer. 1984. Concepts of the chemical structure of lipid A. Rev. Infect. Dis. 6: 432
    OpenUrlCrossRefPubMed
  31. ↵
    Rietschel, E. T., H.-W. Wollenweber, H. Brade, U. Zährinber, B. Lindner, U. Seydel, H. Bradaczek, G. Barnickel, H. Labischinski, P. Giesbrecht. 1984. Structure and conformation of the lipid A component of lipopolysaccharides. R. A. Proctor, ed. In Handbook of Endotoxin Vol. 1: 187 Elsevier Science Publishers, Amsterdam.
    OpenUrl
  32. ↵
    Grabarek, J., G. R. Her, V. N. Reinhold, J. Hawiger. 1990. Endotoxic lipid A interaction with human platelets: structure-function analysis of lipid A homologs obtained from Salmonella minnesota Re 595 lipopolysaccharide. J. Biol. Chem. 265: 8117
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Galanos, C., V. Lehmann, O. Lüderitz, E. T. Rietschel, O. Westphal, H. Brade, L. Brade, M. A. Freudenberg, T. Hansen-Hagge, T. Lüderitz, et al 1984. Endotoxic properties of chemically synthesized lipid A part structures: comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic precursor and free lipid A. Eur. J. Biochem. 140: 221
    OpenUrlPubMed
  34. ↵
    Yang, R.B., M.R. Mark, A. Gray, A. Huang, M.H. Xie, M. Zang, A. Goddard, W. I. Wood, A. L. Gurney, P. J. Godowski. 1998. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395: 284
    OpenUrlCrossRefPubMed
  35. ↵
    Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J. Exp. Med. 189: 1777
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Galanos, C., O. Lüderiz, E. T. Reitschel, O. Westphal. 1977. Newer aspects of the chemistry and biology of bacterial lipopolysaccharides with special reference to their lipid A component. T. W. Goodwin, ed. Biochemistry of lipids II 371 University Park Press, Baltimore.
  37. ↵
    Munford, R. S., C. L. Hall. 1989. Purification of acyloxyacyl hydrolase, a leukocyte enzyme that removes secondary acyl chains from bacterial liopoplysaccharides. J. Biol. Chem. 264: 15613
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Erwin, A. L., R. S. Munford. 1990. Deacylation of structureally diverse liopoplysaccharides by human acyloxyacyl hydrolase. J. Biol. Chem. 265: 16444
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Tanamoto, K.. 1995. Dissociation of endotoxic activities in a chemically synthesized lipid A precuresor after acetylation. Infect. Immun. 63: 690
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 164 (6)
The Journal of Immunology
Vol. 164, Issue 6
15 Mar 2000
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Salmonella-Type Heptaacylated Lipid A Is Inactive and Acts as an Antagonist of Lipopolysaccharide Action on Human Line Cells
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Salmonella-Type Heptaacylated Lipid A Is Inactive and Acts as an Antagonist of Lipopolysaccharide Action on Human Line Cells
Ken-ichi Tanamoto, Satoko Azumi
The Journal of Immunology March 15, 2000, 164 (6) 3149-3156; DOI: 10.4049/jimmunol.164.6.3149

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Salmonella-Type Heptaacylated Lipid A Is Inactive and Acts as an Antagonist of Lipopolysaccharide Action on Human Line Cells
Ken-ichi Tanamoto, Satoko Azumi
The Journal of Immunology March 15, 2000, 164 (6) 3149-3156; DOI: 10.4049/jimmunol.164.6.3149
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Efficient Identification of Tembusu Virus CTL Epitopes in Inbred HBW/B4 Ducks Using a Novel MHC Class I–Restricted Epitope Screening Scheme
  • Poor-Quality Vβ Recombination Signal Sequences and the DNA Damage Response ATM Kinase Collaborate to Establish TCRβ Gene Repertoire and Allelic Exclusion
  • Multifaceted Activities of Seven Nanobodies against Complement C4b
Show more MOLECULAR AND STRUCTURAL IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606